Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE)

Trial Profile

A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Registrational; Therapeutic Use
  • Acronyms SUNSHINE
  • Sponsors Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
  • Most Recent Events

    • 31 Oct 2023 According to a Novartis media release, based on analyses from the largest Phase III program in HS to date, SUNSHINE and SUNRISE study the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults
    • 01 Jun 2023 According to a Novartis media release, based on results from this trial, the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to conventional systemic HS therapy.
    • 26 Apr 2023 According to a Novartis media release, regulatory decision from the US Food and Drug Administration (FDA) expected later this year. Also, The recommendation for Cosentyx in HS will be referred to the European Commission, which is expected to deliver a final decision within 2 months.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top